Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going

Francesco Schettini, Giuseppe Buono, Cinzia Cardalesi, Isacco Desideri, Sabino De Placido, Lucia Del Mastro

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Near 75% of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone receptors (PgR), while up to 20% of BC show an overexpression/amplification of Human Epidermal Growth Factor Receptor 2 (HER2). Around 50% of all HER2-overexpressing BC show the coexistence of both HER2 overexpression/amplification and ER and/or PgR overexpression. Numerous in vitro and in vivo studies suggest the existence of a cross-talk between their downstream pathways, which seem to affect the natural history, response to therapy and outcome of patients affected by this subset of BC. Meta-analyses or subgroup analysis of numerous neo-/adjuvant trials demonstrated significant clinical implications deriving from ER/HER2 co-existence, consisting in a different pattern of relapse and dissimilar outcome in response to anti-HER2 therapy. However, only two randomized trials in early disease and three in advanced disease specifically addressed the issue whether a combined approach with both hormonal and anti-HER2 therapy would have a better therapeutic impact in this subset of BC compared to the lone anti-HER2 or hormonal therapies (HT). None of these trials demonstrated improvements in overall survival, even though several efficacy end-points such as progression free survival, in advanced setting, or pCR rates in neoadjuvant setting, often favored the combined hormonal and anti-HER2 therapeutic approach. In the next few years, a certain number of ongoing randomized trials, both in neoadjuvant and advanced setting, will evaluate the efficacy of new anti-HER2 drugs, T-DM1 and pertuzumab, in combination with HT, helping to improve the therapeutic strategy for this specific subtype of breast tumors.

Original languageEnglish
Pages (from-to)20-26
Number of pages7
JournalCancer Treatment Reviews
Volume46
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Hormones
Breast Neoplasms
Estrogen Receptors
Progesterone Receptors
Therapeutics
human ERBB2 protein
Natural History
Disease-Free Survival
Meta-Analysis
Recurrence
Survival
Pharmaceutical Preparations

Keywords

  • Breast cancer
  • Combination therapy
  • Crosstalk
  • Estrogen receptor
  • HER2
  • Hormone therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer : Where we are now and where we are going. / Schettini, Francesco; Buono, Giuseppe; Cardalesi, Cinzia; Desideri, Isacco; De Placido, Sabino; Del Mastro, Lucia.

In: Cancer Treatment Reviews, Vol. 46, 01.05.2016, p. 20-26.

Research output: Contribution to journalArticle

Schettini, Francesco ; Buono, Giuseppe ; Cardalesi, Cinzia ; Desideri, Isacco ; De Placido, Sabino ; Del Mastro, Lucia. / Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer : Where we are now and where we are going. In: Cancer Treatment Reviews. 2016 ; Vol. 46. pp. 20-26.
@article{f9048c9679004af7bf281dfe38d01011,
title = "Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going",
abstract = "Near 75{\%} of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone receptors (PgR), while up to 20{\%} of BC show an overexpression/amplification of Human Epidermal Growth Factor Receptor 2 (HER2). Around 50{\%} of all HER2-overexpressing BC show the coexistence of both HER2 overexpression/amplification and ER and/or PgR overexpression. Numerous in vitro and in vivo studies suggest the existence of a cross-talk between their downstream pathways, which seem to affect the natural history, response to therapy and outcome of patients affected by this subset of BC. Meta-analyses or subgroup analysis of numerous neo-/adjuvant trials demonstrated significant clinical implications deriving from ER/HER2 co-existence, consisting in a different pattern of relapse and dissimilar outcome in response to anti-HER2 therapy. However, only two randomized trials in early disease and three in advanced disease specifically addressed the issue whether a combined approach with both hormonal and anti-HER2 therapy would have a better therapeutic impact in this subset of BC compared to the lone anti-HER2 or hormonal therapies (HT). None of these trials demonstrated improvements in overall survival, even though several efficacy end-points such as progression free survival, in advanced setting, or pCR rates in neoadjuvant setting, often favored the combined hormonal and anti-HER2 therapeutic approach. In the next few years, a certain number of ongoing randomized trials, both in neoadjuvant and advanced setting, will evaluate the efficacy of new anti-HER2 drugs, T-DM1 and pertuzumab, in combination with HT, helping to improve the therapeutic strategy for this specific subtype of breast tumors.",
keywords = "Breast cancer, Combination therapy, Crosstalk, Estrogen receptor, HER2, Hormone therapy",
author = "Francesco Schettini and Giuseppe Buono and Cinzia Cardalesi and Isacco Desideri and {De Placido}, Sabino and {Del Mastro}, Lucia",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.ctrv.2016.03.012",
language = "English",
volume = "46",
pages = "20--26",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer

T2 - Where we are now and where we are going

AU - Schettini, Francesco

AU - Buono, Giuseppe

AU - Cardalesi, Cinzia

AU - Desideri, Isacco

AU - De Placido, Sabino

AU - Del Mastro, Lucia

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Near 75% of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone receptors (PgR), while up to 20% of BC show an overexpression/amplification of Human Epidermal Growth Factor Receptor 2 (HER2). Around 50% of all HER2-overexpressing BC show the coexistence of both HER2 overexpression/amplification and ER and/or PgR overexpression. Numerous in vitro and in vivo studies suggest the existence of a cross-talk between their downstream pathways, which seem to affect the natural history, response to therapy and outcome of patients affected by this subset of BC. Meta-analyses or subgroup analysis of numerous neo-/adjuvant trials demonstrated significant clinical implications deriving from ER/HER2 co-existence, consisting in a different pattern of relapse and dissimilar outcome in response to anti-HER2 therapy. However, only two randomized trials in early disease and three in advanced disease specifically addressed the issue whether a combined approach with both hormonal and anti-HER2 therapy would have a better therapeutic impact in this subset of BC compared to the lone anti-HER2 or hormonal therapies (HT). None of these trials demonstrated improvements in overall survival, even though several efficacy end-points such as progression free survival, in advanced setting, or pCR rates in neoadjuvant setting, often favored the combined hormonal and anti-HER2 therapeutic approach. In the next few years, a certain number of ongoing randomized trials, both in neoadjuvant and advanced setting, will evaluate the efficacy of new anti-HER2 drugs, T-DM1 and pertuzumab, in combination with HT, helping to improve the therapeutic strategy for this specific subtype of breast tumors.

AB - Near 75% of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone receptors (PgR), while up to 20% of BC show an overexpression/amplification of Human Epidermal Growth Factor Receptor 2 (HER2). Around 50% of all HER2-overexpressing BC show the coexistence of both HER2 overexpression/amplification and ER and/or PgR overexpression. Numerous in vitro and in vivo studies suggest the existence of a cross-talk between their downstream pathways, which seem to affect the natural history, response to therapy and outcome of patients affected by this subset of BC. Meta-analyses or subgroup analysis of numerous neo-/adjuvant trials demonstrated significant clinical implications deriving from ER/HER2 co-existence, consisting in a different pattern of relapse and dissimilar outcome in response to anti-HER2 therapy. However, only two randomized trials in early disease and three in advanced disease specifically addressed the issue whether a combined approach with both hormonal and anti-HER2 therapy would have a better therapeutic impact in this subset of BC compared to the lone anti-HER2 or hormonal therapies (HT). None of these trials demonstrated improvements in overall survival, even though several efficacy end-points such as progression free survival, in advanced setting, or pCR rates in neoadjuvant setting, often favored the combined hormonal and anti-HER2 therapeutic approach. In the next few years, a certain number of ongoing randomized trials, both in neoadjuvant and advanced setting, will evaluate the efficacy of new anti-HER2 drugs, T-DM1 and pertuzumab, in combination with HT, helping to improve the therapeutic strategy for this specific subtype of breast tumors.

KW - Breast cancer

KW - Combination therapy

KW - Crosstalk

KW - Estrogen receptor

KW - HER2

KW - Hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=84962376083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962376083&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.03.012

DO - 10.1016/j.ctrv.2016.03.012

M3 - Article

AN - SCOPUS:84962376083

VL - 46

SP - 20

EP - 26

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -